- Home
- AXIN vs CERS Comparison
AXIN vs CERS Comparison
Compare AXIN & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIN
- CERS
- Stock Information
- Founded
- AXIN 2025
- CERS 1991
- Country
- AXIN United Kingdom
- CERS United States
- Employees
- AXIN N/A
- CERS N/A
- Industry
- AXIN
- CERS EDP Services
- Sector
- AXIN
- CERS Technology
- Exchange
- AXIN Nasdaq
- CERS Nasdaq
- Market Cap
- AXIN 272.1M
- CERS 276.0M
- IPO Year
- AXIN 2025
- CERS 1997
- Fundamental
- Price
- AXIN $10.07
- CERS $1.47
- Analyst Decision
- AXIN
- CERS Buy
- Analyst Count
- AXIN 0
- CERS 1
- Target Price
- AXIN N/A
- CERS $4.00
- AVG Volume (30 Days)
- AXIN 55.7K
- CERS 1.2M
- Earning Date
- AXIN 01-01-0001
- CERS 11-06-2025
- Dividend Yield
- AXIN N/A
- CERS N/A
- EPS Growth
- AXIN N/A
- CERS N/A
- EPS
- AXIN N/A
- CERS N/A
- Revenue
- AXIN N/A
- CERS $192,510,000.00
- Revenue This Year
- AXIN N/A
- CERS $19.07
- Revenue Next Year
- AXIN N/A
- CERS $12.03
- P/E Ratio
- AXIN N/A
- CERS N/A
- Revenue Growth
- AXIN N/A
- CERS 13.25
- 52 Week Low
- AXIN $9.93
- CERS $1.12
- 52 Week High
- AXIN $10.07
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- AXIN N/A
- CERS 47.25
- Support Level
- AXIN N/A
- CERS $1.48
- Resistance Level
- AXIN N/A
- CERS $1.55
- Average True Range (ATR)
- AXIN 0.00
- CERS 0.08
- MACD
- AXIN 0.00
- CERS -0.02
- Stochastic Oscillator
- AXIN 0.00
- CERS 25.00
About AXIN Axiom Intelligence Acquisition Corp 1 Class A Ordinary Shares
Axiom Intelligence Acquisition Corp 1 is a blank check company.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.